| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 69, 685-689, Copyright © 1975 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
BS Bull, WM Huse, FS Brauer and RA Korpman
Because the administration of heparin and protamine according to a set
protocol will fail to anticoagulate safely or neutralize appropriately a
significant number of patients, a method of monitoring heparin therapy
during cardiopulmonary bypass is presented. A dose response curve relating
heparin dosage to its effect on the activated coagulation time (ACT) can be
determined with sufficient accuracy for clinical purposes from three ACT's.
Preparation of such a curve makes it possible to maintain anticoagulation
in a safe range during bypass and minimizes the number of monitoring tests
of coagulation required. At the conclusion of bypass, this curve can be
used to predict the precise amount of protamine needed for neutralization.
Freed from the confusing effects of hyperheparinemia or protamine excess,
the physician can diagnose and treat postoperative bleeding problems much
more readily.
ARTICLES
Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage
This article has been cited by other articles:
|
|
 |
|
  J. W. Hammon Extracorporeal Circulation: Perfusion System Card. Surg. Adult, January 1, 2008; 3(2008): 350 - 370. [Full Text]
|
|
|
|
 |
|
 M. L. Schlunt and S. D. Brauer Anesthetic management for the pediatric patient undergoing deep hypothermic circulatory arrest. Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2007; 11(1): 16 - 22. [Abstract] [PDF]
|
|
|
|
 |
|
 C. W. Baird, D. Zurakowski, B. Robinson, S. Gandhi, L. Burdis-Koch, J. Tamblyn, R. Munoz, K. Fortich, and F. A. Pigula Anticoagulation and Pediatric Extracorporeal Membrane Oxygenation: Impact of Activated Clotting Time and Heparin Dose on Survival Ann. Thorac. Surg., March 1, 2007; 83(3): 912 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.N. Shuhaibar, M. Hargrove, M.H. Millat, A. O'Donnell, and T. Aherne How much heparin do we really need to go on pump? A rethink of current practices Eur. J. Cardiothorac. Surg., November 1, 2004; 26(5): 947 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Svenmarker, M Appelblad, E Jansson, and S Haggmark Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec(R) ACT and Hemochron(R) Jr apparatus Perfusion, September 1, 2004; 19(5): 289 - 294. [Abstract] [PDF]
|
|
|
|
 |
|
 A. S. Arbab, G. T. Yocum, H. Kalish, E. K. Jordan, S. A. Anderson, A. Y. Khakoo, E. J. Read, and J. A. Frank Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI Blood, August 15, 2004; 104(4): 1217 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Neema, P. K. Sinha, and R. C. Rathod Activated Clotting Time During Cardiopulmonary Bypass: Is Repetition Necessary During Open Heart Surgery? Asian Cardiovasc Thorac Ann, March 1, 2004; 12(1): 47 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ranucci, A. Ditta, A. Boncilli, M. Cotza, G. Carboni, S. Brozzi, C. Bonifazi, and A. Tiezzi Determinants of antithrombin consumption in cardiac operations requiring cardiopulmonary bypass Perfusion, January 1, 2004; 19(1): 47 - 52. [Abstract] [PDF]
|
|
|
|
|
|
P. J. Santrach Devices for Monitoring Heparin and Protamine in the Operating Room Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 379 - 385. [Abstract] [PDF]
|
|
|
|
|
|
W. C. Oliver Jr Overview of Heparin and Protamine Management and Dosing Regimens in Pediatric Cardiac Surgical Patients Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 387 - 410. [Abstract] [PDF]
|
|
|
|
|
|
L. Brownstein, T. P Bartholomew, D. G Silver, and C. M Berry A case report of mitral valve replacement in a patient with lupus antibody syndrome Perfusion, December 1, 2003; 18(6): 373 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 J.-L. Vincent, M. M. Wilkes, and R. J. Navickis Safety of human albumin--serious adverse events reported worldwide in 1998-2000{dagger} Br. J. Anaesth., November 1, 2003; 91(5): 625 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P D Raymond, M J Ray, S N Callen, and N A Marsh Heparin monitoring during cardiac surgery. Part 2: calculating the overestimation of heparin by the activated clotting time Perfusion, September 1, 2003; 18(5): 277 - 281. [Abstract] [PDF]
|
|
|
|
|
|
E. A. Hessel II and L. H. Edmunds Jr. Extracorporeal Circulation: Perfusion Systems Card. Surg. Adult, January 1, 2003; 2(2003): 317 - 338. [Full Text]
|
|
|
|
|
|
P. Svenarud and E. Ovrum Clinical Effects of Different Protamine Doses After Cardiopulmonary Bypass Asian Cardiovasc Thorac Ann, June 1, 2002; 10(2): 119 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Heres, K. Speight, D. Benckart, J. Marquez, and G. P. Gravlee The Clinical Onset of Heparin Is Rapid Anesth. Analg., June 1, 2001; 92(6): 1391 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Codispoti, C. A. Ludlam, D. Simpson, and P. S. Mankad Individualized heparin and protamine management in infants and children undergoing cardiac operations Ann. Thorac. Surg., March 1, 2001; 71(3): 922 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Owings, M. E. Pollock, R. C. Gosselin, K. Ireland, J. S. Jahr, and E. C. Larkin Anticoagulation of Children Undergoing Cardiopulmonary Bypass Is Overestimated by Current Monitoring Techniques Arch Surg, September 1, 2000; 135(9): 1042 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Codispoti and P. S Mankad Management of anticoagulation and its reversal during paediatric cardiopulmonary bypass: a review of current UK practice Perfusion, May 1, 2000; 15(3): 191 - 201. [Abstract] [PDF]
|
|
|
|
|
|
C Gruenwald, V de Souza, A K. Chan, and M Andrew Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass Perfusion, May 1, 2000; 15(3): 203 - 209. [Abstract] [PDF]
|
|
|
|
|
|
M. Ranucci, G. Isgro, A. Cazzaniga, G. Soro, L. Menicanti, and A. Frigiola Predictors for heparin resistance in patients undergoing coronary artery bypass grafting Perfusion, December 1, 1999; 14(6): 437 - 442. [Abstract] [PDF]
|
|
|
|
|
|
S. Chauhan, T. K. Ghosh, S. Srivastava, M. Sahu, S. R. Mohanty, A. Mathur, N. Saxena, and P. Venugopal Heparin Dosing and Postoperative Blood Loss in Patients Taking Aspirin Asian Cardiovasc Thorac Ann, December 1, 1998; 6(4): 270 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Weisinger and J. H. Levy Current Hematologic Issues in Cardiac Surgery and Cardiopulmonary Bypass Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1998; 2(4): 259 - 271. [Abstract] [PDF]
|
|
|
|
 |
|
 A. D. Kugelmass and G. E. Raskob Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty or Coronary Stent Placement Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(1_suppl): S24 - S31. [PDF]
|
|
|
|
|
|
M. S. Irani Antithrombin Concentrates in Heparin-Resistant Cardiopulmonary Bypass Patients Clinical and Applied Thrombosis/Hemostasis, April 1, 1996; 2(2): 103 - 106. [Abstract] [PDF]
|
|
|
|
|
|
B. P. Bidstrup Monitoring of Systemic Anticoagulation During Cardiopulmonary Bypass Ann. Thorac. Surg., March 1, 1996; 61(3): 781 - 782. [Full Text]
|
|
|
|
|
|
G. J. Despotis, A. L. Alsoufiev, E. Spitznagel, L. T. Goodnough, and D. G. Lappas Response of Kaolin ACT to Heparin: Evaluation With an Automated Assay and Higher Heparin Doses Ann. Thorac. Surg., March 1, 1996; 61(3): 795 - 799. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. R. Jobes, G. L. Aitken, and G. W. Shaffer Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion patients undergoing primary cardiac operations J. Thorac. Cardiovasc. Surg., July 1, 1995; 110(1): 36 - 45. [Abstract] [Full Text]
|
|
|
|
|
|
G. J. Despotis, J. H. Joist, C. W. Hogue Jr., A. Alsoufiev, K. Kater, L. T. Goodnough, S. A. Santoro, E. Spitznagel, M. Rosenblum, and D. G. Lappas The impact of heparin concentration and activated clotting time monitoring on blood conservation: A prospective, randomized evaluation in patients undergoing cardiac operation J. Thorac. Cardiovasc. Surg., July 1, 1995; 110(1): 46 - 54. [Abstract] [Full Text]
|
|
|
|
|
|
R. Pifarre State-of-the-Art Review: Optimal Anticoagulation in Cardiovascular Surgery Clinical and Applied Thrombosis/Hemostasis, June 1, 1995; 1(3): 173 - 178. [Abstract] [PDF]
|
|
|
|
|
|
G. J. Despotis, A. L. Summerfield, J. H. Joist, L. T. Goodnough, S. A. Santoro, E. Spitznagel, J. L. Cox, and D. G. Lappas Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1076 - 1082. [Abstract] [Full Text]
|
|
|
|
|
|
G. Singh, M. Gayler, R. Wyatt, and T. Spyt Clinical significance of heparin in the residual pump oxygenator blood, reinfused postoperatively after cardiopulmonary bypass Perfusion, July 1, 1994; 9(4): 271 - 275. [Abstract] [PDF]
|
|
|
|
|
|
S. O. Turner-Gomes, L. Mitchell, W. G. Williams, and M. Andrew Thrombin regulation in congenital heart disease after cardiopulmonary bypass operations J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 562 - 568. [Abstract] [Full Text]
|
|
|
|
|
|
E. M. Retera, G. A Yerman, and W. R. Dassen Heparin-protamine management: a comparison study of three different heparin-protamine management protocols Perfusion, September 1, 1993; 8(5): 371 - 375. [Abstract] [PDF]
|
|
|
|
|
|
C. Prentice, M. Orchard, and C. Goodchild Haemostatic dysfunction and cardiopulmonary bypass: mechanisms and therapeutic choices Perfusion, May 1, 1993; 8(1_suppl): 28 - 35. [Abstract] [PDF]
|
|
|
|
|
|
P. Kesteven Haemostatic changes during cardiopulmonary bypass Perfusion, January 1, 1990; 5(1_suppl): 9 - 19. [PDF]
|
|
|
|
|
|
C. Aren Review article : Heparin and protamine during cardiac surgery Perfusion, July 1, 1989; 4(3): 171 - 181. [PDF]
|
|
|
|
|
|
T. Hooper, J. Conroy, B. McArdle, A. Dell, B. Watson, D. Pearson, and P. Kesteven The use of the Hemochron in assessment of heparin reversal after cardiopulmonary bypass Perfusion, October 1, 1988; 3(4): 295 - 300. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Lincoln and R. Korpman Computers, health care, and medical information science Science, October 17, 1980; 210(4467): 257 - 263. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
